Medac Pharma, Inc., a privately held pharmaceutical company, has announced the launch of its lead product Rasuvo™ (methotrexate) injection for patients with rheumatoid arthritis (RA), poly-articular-course juvenile idiopathic arthritis (pJIA) and psoriasis in the U.S.
Rasuvo is a single dose, subcutaneous methotrexate (MTX) auto injector offering the widest dose range in a subcutaneous MTX therapy. It is available in 10 dosage strengths, ranging from 7.5 mg to 30 mg in 2.5 mg increments. Rasuvo is available immediately through drug distribution centers throughout the U.S.
"We are pleased to bring Rasuvo to the market and provide another treatment option for patients and healthcare providers to manage rheumatoid arthritis, poly-articular-course juvenile idiopathic arthritis and psoriasis," said Ms. Terri Shoemaker, President and CEO of Medac Pharma. "The swift, successful execution of our commercial plan is a testament of our ability to leverage our internally-built sales, marketing and managed care account teams. Rasuvo is backed by our extensive resources and services, proving our commitment to patients." Ms. Shoemaker also stated that the recently-founded commercialization efforts provide a strategic platform for the company's growing portfolio.
Augmenting the launch, Medac Pharma has developed CORE Connections, a comprehensive program providing information, materials and assistance to help patients and healthcare providers obtain and use Rasuvo. Some of the components of CORE Connections include patient access and pharmacy support programs, reimbursement and copay assistance.
SOURCE Medac Pharma, Inc.